Glaxo tenders UK PR for top medicine products

Glaxo Wellcome is holding pitches for agencies to handle PR for its main UK therapy areas on combined fees of at least pounds 300,000.

Glaxo Wellcome is holding pitches for agencies to handle PR for its

main UK therapy areas on combined fees of at least pounds 300,000.



Pitches for three UK product PR accounts are being held, while one

pan-European account is known to be the subject of an intense round of

pitching.



Up for pitch is the UK over-the-counter (OTC) therapy range, which

includes products like Zantac 75, a treatment for indigestion, and

Zovirax, for treating cold-sores.



Agencies are also competing to handle UK PR for HIV treatments such as

Combivir, and several new products set to be launched.



The third UK PR account open to pitch is for influenza drug Relenza,

which is the first new treatment for flu for several years.



There are no incumbent agencies on any of these accounts.



Glaxo Wellcome communications manager Philip Thomson said: ’We are

looking for an agency that can offer creativity and an ability to think

strategically in the face of increasing competition.’



Manning Selvage and Lee, Chandler Chicco, Sante Communications, Shire

Hall, Hill and Knowlton, Countrywide Porter Novelli and Lowe Fusion

Healthcare are all on Glaxo Wellcome’s pitch roster.



Marketing plans are still being examined for other products within

neurology and psychiatry, and further PR accounts could be tendered.



Glaxo currently retains five agencies working on six separate

accounts.



Chandler Chicco and Countrywide Porter Novelli share the UK PR account

for the respiratory therapy area, while Sante Communications was

appointed last week (PR Week 23, April) to run a global campaign for the

range.



Sante Communications also promotes Glaxo’s neurology and psychiatric

range on a global basis. Lowe Fusion handles the migraine treatment

area.



Shire Hall International handles global PR for Glaxo’s HIV therapy area.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.